KEYNOTE-407 Study of Frontline Pembrolizumab and Chemotherapy in Advanced NSCLC

Dr Velcheti reviews data on the chemoimmunotherapy treatment of squamous NSCLC from the KEYNOTE-407 study.

Related Videos
View All
Related Content